Suppr超能文献

钙调磷酸酶抑制剂相关肾功能障碍的肝移植患者中钙调磷酸酶抑制剂最小化:一项荟萃分析。

Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis.

机构信息

Organ Transplant Center, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

出版信息

PLoS One. 2011;6(9):e24387. doi: 10.1371/journal.pone.0024387. Epub 2011 Sep 9.

Abstract

BACKGROUND

Introduction of calcineurin-inhibitor (CNI) has made transplantation a miracle in the past century. However, the side effects of long-term use of CNI turn out to be one of the major challenges in the current century. Among these, renal dysfunction attracts more and more attention. Herein, we undertook a meta-analysis to evaluate the efficacy and safety of calcineurin-inhibitor (CNI) minimization protocols in liver transplant recipients with CNI-related renal dysfunction.

METHODS

We included randomized trials with no year and language restriction. All data were analyzed using random effect model by Review Manager 5.0. The primary endpoints were glomerular filtration rate (GFR), serum creatinine level (sCr) and creatinine clearance rate (CrCl), and the secondary endpoints were acute rejection episodes, incidence of infection and patient survival at the end of follow-up.

RESULTS

GFR was significantly improved in CNI minimization group than in routine CNI regimen group (Z = 5.45, P<0.00001; I(2) = 0%). Likely, sCr level was significantly lower in the CNI minimization group (Z = 2.84, P = 0.005; I(2) = 39%). However, CrCl was not significantly higher in the CNI minimization group (Z = 1.59, P = 0.11; I(2) = 0%). Both acute rejection episodes and patient survival were comparable between two groups (rejection: Z = 0.01, P = 0.99; I(2) = 0%; survival: Z = 0.28, P = 0.78; I(2) = 0%, respectively). However, current CNI minimization protocols may be related to a higher incidence of infections (Z = 3.06, P = 0.002; I(2) = 0%).

CONCLUSION

CNI minimization can preserve or even improve renal function in liver transplant patients with renal impairment, while sharing similar short term acute rejection rate and patient survival with routine CNI regimen.

摘要

背景

钙调磷酸酶抑制剂(CNI)的引入使得移植在过去一个世纪成为了一个奇迹。然而,CNI 的长期使用所带来的副作用,在本世纪成为了一个主要的挑战。在这些副作用中,肾功能障碍引起了越来越多的关注。在此,我们进行了一项荟萃分析,以评估钙调磷酸酶抑制剂(CNI)最小化方案在伴有 CNI 相关肾功能障碍的肝移植受者中的疗效和安全性。

方法

我们纳入了无年限和语言限制的随机试验。所有数据均使用 Review Manager 5.0 软件通过随机效应模型进行分析。主要终点为肾小球滤过率(GFR)、血清肌酐水平(sCr)和肌酐清除率(CrCl),次要终点为急性排斥反应发作、感染发生率和随访结束时的患者生存率。

结果

与常规 CNI 方案组相比,CNI 最小化组的 GFR 显著改善(Z=5.45,P<0.00001;I²=0%)。同样,CNI 最小化组的 sCr 水平显著降低(Z=2.84,P=0.005;I²=39%)。然而,CNI 最小化组的 CrCl 并没有显著升高(Z=1.59,P=0.11;I²=0%)。两组之间的急性排斥反应发作和患者生存率相当(排斥反应:Z=0.01,P=0.99;I²=0%;生存率:Z=0.28,P=0.78;I²=0%)。然而,目前的 CNI 最小化方案可能与更高的感染发生率相关(Z=3.06,P=0.002;I²=0%)。

结论

CNI 最小化可以保留甚至改善伴有肾功能损害的肝移植患者的肾功能,同时与常规 CNI 方案相比,具有相似的短期急性排斥反应率和患者生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验